These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28792260)

  • 1. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
    Hu B; Younes A; Westin JR; Turturro F; Claret L; Feng L; Fowler N; Neelapu S; Romaguera J; Hagemeister FB; Rodriguez MA; Samaniego F; Fayad LE; Copeland AR; Nastoupil LJ; Nieto Y; Fanale MA; Oki Y
    Leuk Lymphoma; 2018 Apr; 59(4):863-870. PubMed ID: 28792260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
    Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
    Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
    Oki Y; Buglio D; Fanale M; Fayad L; Copeland A; Romaguera J; Kwak LW; Pro B; de Castro Faria S; Neelapu S; Fowler N; Hagemeister F; Zhang J; Zhou S; Feng L; Younes A
    Clin Cancer Res; 2013 Dec; 19(24):6882-90. PubMed ID: 24097867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
    Loss JF; Santos PP; Leone LD; Brunetto AL
    Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
    Stamatoullas A; Ghesquières H; Feugier P; André M; Le Bras F; Gac AC; Borel C; Gastinne T; Quittet P; Morschhauser F; Ribrag V; Guidez S; Nicolas-Virelizier E; Berriolo-Riedinger A; Vander Borght T; Edeline V; Brice P
    Leuk Lymphoma; 2022 Dec; 63(13):3063-3071. PubMed ID: 35975738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
    Shea TC; Beaven AW; Moore DT; Serody JS; Gabriel DA; Chao N; Gockerman JP; Garcia RA; Rizzieri DA
    Leuk Lymphoma; 2009 May; 50(5):741-8. PubMed ID: 19358012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
    Mi M; Zhang C; Liu Z; Wang Y; Li J; Zhang L
    Medicine (Baltimore); 2020 Dec; 99(49):e23412. PubMed ID: 33285732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.
    Maly JJ; Christian BA; Zhu X; Wei L; Sexton JL; Jaglowski SM; Devine SM; Fehniger TA; Wagner-Johnston ND; Phelps MA; Bartlett NL; Blum KA
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):347-353. PubMed ID: 28622959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of panobinostat in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):5-6. PubMed ID: 24870872
    [No Abstract]   [Full Text] [Related]  

  • 13. Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas.
    Loo S; Lim A; Lee ST; Grigg A
    Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e190-e194. PubMed ID: 36707275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
    Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
    Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
    Bryan LJ; Casulo C; Allen PB; Smith SE; Savas H; Dillehay GL; Karmali R; Pro B; Kane KL; Bazzi LA; Chmiel JS; Palmer BA; Mehta J; Gordon LI; Winter JN
    JAMA Oncol; 2023 May; 9(5):683-691. PubMed ID: 36928527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
    Hirota T; Takeuchi M; Iwata A; Kitagawa S; Sato T; Konno K; Sawada K; Kobayashi S; Hamaguchi N; Agata H; Katano N; Fujimoto T
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):385-90. PubMed ID: 9492832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.
    Zaja F; Salvi F; Rossi M; Sabattini E; Evangelista A; Ciccone G; Angelucci E; Gaidano G; Zanni M; Ladetto M; Chiappella A; Vitolo U; Zinzani PL; Califano C; Tucci A; Patti C; Pileri SA; Lenti V; Piccaluga PP; Cavallo F; Volpetti S; Perali G; Assouline S; Mann KK; Morin R; Alcaide M; Bushell K; Fanin R; Levis A
    Leuk Lymphoma; 2018 Dec; 59(12):2904-2910. PubMed ID: 29616865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.